UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jur ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_4480560867daa7897cdca7c4f81be1aa.html ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_be6fedd1fb77d56b713eae8e2fabe258.html ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Geoff Meacham - Bank of America Chris Schott - JPMorgan Tyler Van Buren - TD Cowen Terrence F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jurisdic ...

Gilead Sciences, Inc. (NASDAQ:GILD) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 1:40 PM ET Company Participants Daniel O’Day - Chairman & CEO Merdad Parsey - Chief Medical Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good morning, everyone. Thanks for joining us. I’m Salveen Richter, Biotechnology Analyst at Goldman Sachs, and we're really pleased to have Gilead with us. So we have Dan O’Day, Chairman and CEO as well as Merdad Parsey, C ...

Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies Global Healthcare Conference June 7, 2023 11:00 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Michael Yee - Jefferies Michael Yee Thank you very much. I want to get started on the next session. It's Michael Yee, Managing Director. I'm the senior biotechnology analyst at Jefferies. I'm very happy to have with us here at Gilead Sciences, Johanna Mercier, the Chief Commercial Officer. And I thought that would be ...

Gilead Sciences, Inc. (NASDAQ:GILD) RBC Capital Markets Global Healthcare Conference May 16, 2023 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Good morning. I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets, and welcome again. Our next presenting company is Gilead. Really pleased to have with us their Chief Medical Officer, Merdad Parsey. Merdad, thank you again. Merdad ...

Gilead Sciences, Inc. (NASDAQ:GILD) BofA Securities 2023 Health Care Conference May 9, 2023 2:20 PM ET Company Participants Andy Dickinson - CFO Conference Call Participants Geoff Meacham - Bank of America Geoff Meacham Welcome to the morning session of the BofA Healthcare Conference. So my name is Geoff Meacham. I'm the senior biopharma analyst. And we're thrilled today to have Gilead Sciences. And up on stage with me is Andy Dickinson. Andy, welcome. Andy Dickinson Thank you. Great to be here. Thanks for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jurisdi ...